How to buy Iovance Biotherapeutics stock | $26.2

Iovance Biotherapeutics Inc is a biotechnology business based in the US. Iovance Biotherapeutics shares (IOVA) are listed on the NASDAQ and all prices are listed in US Dollars. Iovance Biotherapeutics employs 241 staff and has a market cap (total outstanding shares value) of 0.00.

Iovance Biotherapeutics stock price (NASDAQ: IOVA)

Use our graph to track the performance of IOVA stocks over time.

Iovance Biotherapeutics shares at a glance

• Key figures

Information last updated 2021-10-17.

Latest market close	$26.20
52-week range	$17.24 - $54.21
50-day moving average	$24.91
200-day moving average	$24.95
Wall St. target price	$40.31
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-1.91

Buy Iovance Biotherapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Iovance Biotherapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Iovance Biotherapeutics price performance over time

Historical closes compared with the close of $26.2 from 2021-10-19

1 week (2021-10-13)	-0.49%
1 month (2021-09-20)	9.17%
3 months (2021-07-20)	10.32%
6 months (2021-04-20)	-13.16%

1 year (2020-10-20)	-30.80%
2 years (2019-10-18)	33.88%
3 years (2018-10-19)	164.91%
5 years (2016-10-20)	303.08%

Iovance Biotherapeutics financials

Gross profit TTM	$0
Return on assets TTM	-21.29%
Return on equity TTM	-37.77%
Profit margin	0%
Book value	$4.81
Market capitalisation	$4.1 billion

TTM: trailing 12 months

Shorting Iovance Biotherapeutics shares

There are currently 14.6 million Iovance Biotherapeutics shares held short by investors – that's known as Iovance Biotherapeutics's "short interest". This figure is 5.5% down from 15.5 million last month.

There are a few different ways that this level of interest in shorting Iovance Biotherapeutics shares can be evaluated.

Iovance Biotherapeutics's "short interest ratio" (SIR)

Iovance Biotherapeutics's "short interest ratio" (SIR) is the quantity of Iovance Biotherapeutics shares currently shorted divided by the average quantity of Iovance Biotherapeutics shares traded daily (recently around 1.4 million). Iovance Biotherapeutics's SIR currently stands at 10.73. In other words for every 100,000 Iovance Biotherapeutics shares traded daily on the market, roughly 10730 shares are currently held short.

However Iovance Biotherapeutics's short interest can also be evaluated against the total number of Iovance Biotherapeutics shares, or, against the total number of tradable Iovance Biotherapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Iovance Biotherapeutics's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Iovance Biotherapeutics shares in existence, roughly 90 shares are currently held short) or 0.1154% of the tradable shares (for every 100,000 tradable Iovance Biotherapeutics shares, roughly 115 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Iovance Biotherapeutics.

Find out more about how you can short Iovance Biotherapeutics stock.

Iovance Biotherapeutics share dividends

We're not expecting Iovance Biotherapeutics to pay a dividend over the next 12 months.

Have Iovance Biotherapeutics's shares ever split?

Iovance Biotherapeutics's shares were split on a 1:100 basis on 25 September 2013. So if you had owned 100 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Iovance Biotherapeutics shares – just the quantity. However, indirectly, the new 9900% higher share price could have impacted the market appetite for Iovance Biotherapeutics shares which in turn could have impacted Iovance Biotherapeutics's share price.

Iovance Biotherapeutics share price volatility

Over the last 12 months, Iovance Biotherapeutics's shares have ranged in value from as little as $17.24 up to $54.2081. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Iovance Biotherapeutics's is 0.8317. This would suggest that Iovance Biotherapeutics's shares are less volatile than average (for this exchange).

Iovance Biotherapeutics overview

Iovance Biotherapeutics, Inc. , a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M. D.

Frequently asked questions

What percentage of Iovance Biotherapeutics is owned by insiders or institutions?
Currently 0.599% of Iovance Biotherapeutics shares are held by insiders and 107.153% by institutions. How many people work for Iovance Biotherapeutics?
Latest data suggests 241 work at Iovance Biotherapeutics. When does the fiscal year end for Iovance Biotherapeutics?
Iovance Biotherapeutics's fiscal year ends in December. Where is Iovance Biotherapeutics based?
Iovance Biotherapeutics's address is: 999 Skyway Road, San Carlos, CA, United States, 94070 What is Iovance Biotherapeutics's ISIN number?
Iovance Biotherapeutics's international securities identification number is: US4622601007 What is Iovance Biotherapeutics's CUSIP number?
Iovance Biotherapeutics's Committee on Uniform Securities Identification Procedures number is: 37182R102